​

BioNTech SE (BNTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipChartTranscripts

BNTX Stock Forecast

BioNTech SE (BNTX) stock forecast, based on 24 Wall Street analysts, predicts a 12-month average price target of $132.33, with a high of $158.00 and a low of $96.00. This represents a 35.65% increase from the last price of $97.55.

$80 $96 $112 $128 $144 $160 High: $158 Avg: $132.33 Low: $96 Last Closed Price: $97.55

BNTX Stock Rating

BioNTech SE stock's rating consensus is Buy, based on 24 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 21 Buy (87.50%), 3 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 24 0 3 21 Strong Sell Sell Hold Buy Strong Buy

BNTX Price Target Upside V Benchmarks

TypeNameUpside
StockBioNTech SE35.65%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-416
Avg Price Target-$128.75$135.13
Last Closing Price$97.55$97.55$97.55
Upside/Downside-31.98%38.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 261145--20
Jun, 261135--19
May, 261133-118
Apr, 261135--19
Mar, 261145--20
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 27, 2026UBS$135.00$92.2546.34%38.39%
May 21, 2026Bernstein$96.00$90.935.58%-1.59%
May 06, 2026Canaccord Genuity$158.00$95.5065.45%61.97%
Apr 10, 2026Terence FlynnMorgan Stanley$126.00$93.3834.93%29.16%
Mar 11, 2026Evan David SeigermanBMO Capital$128.00$90.5241.41%31.21%
Mar 10, 2026Akash TewariJefferies$138.00$83.8964.50%41.47%
Mar 10, 2026Asthika GoonewardeneTruist Financial$155.00$83.8984.77%58.89%
Mar 10, 2026Morgan Stanley$128.00$83.8952.58%31.21%
Feb 02, 2026Leerink Partners$113.00$113.75-0.66%15.84%
Jan 16, 2026Goldman Sachs$142.00$106.0733.87%45.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 05, 2026BernsteinMarket PerformMarket Performhold
May 27, 2026UBSBuyBuyupgrade
May 21, 2026BernsteinMarket Performinitialise
Apr 10, 2026Morgan StanleyOverweightOverweighthold
Mar 11, 2026BMO CapitalOutperformOutperformhold
Mar 10, 2026JefferiesBuyBuyhold
Mar 10, 2026Raymond JamesOutperformOutperformhold
Mar 10, 2026Morgan StanleyBuyBuyhold
Mar 10, 2026Morgan StanleyOverweightOverweighthold
Jan 16, 2026Goldman SachsNeutralBuyupgrade

Financial Forecast

EPS Forecast

$-10 $2 $14 $26 $38 $50 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$42.18$38.78------
Avg Forecast$36.10$34.97$4.31$-3.16$-3.35$-3.47$-3.25$-2.46
High Forecast$48.32$46.41$4.81$-1.30$-0.06$-0.33$0.74$-1.59
Low Forecast$23.91$25.17$3.93$-4.51$-6.55$-8.43$-9.21$-3.52
Surprise %16.84%10.90%------

Revenue Forecast

$0 $5B $10B $15B $20B $25B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.98B$17.31B$3.82B-----
Avg Forecast$19.46B$17.85B$4.62B$2.74B$2.67B$2.67B$2.88B$3.64B
High Forecast$24.53B$22.33B$5.53B$2.84B$3.59B$2.77B$2.96B$4.86B
Low Forecast$14.41B$14.00B$4.37B$2.57B$1.99B$2.58B$2.80B$2.65B
Surprise %-2.50%-3.00%-17.39%-----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$10.29B$9.43B$930.30M-----
Avg Forecast$8.76B$8.49B$1.06B$-418.00M$-827.47M$-822.38M$-750.84M$-595.90M
High Forecast$11.73B$11.26B$1.17B$-315.60M$-13.70M$-80.17M$180.75M$-385.97M
Low Forecast$5.80B$6.11B$953.15M$-1.10B$-1.59B$-2.05B$-2.23B$-855.45M
Surprise %17.46%11.15%-12.31%-----

BNTX Forecast FAQ

Is BioNTech SE stock a buy?

BioNTech SE stock has a consensus rating of Buy, based on 24 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 21 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BioNTech SE is a favorable investment for most analysts.

What is BioNTech SE's price target?

BioNTech SE's price target, set by 24 Wall Street analysts, averages $132.33 over the next 12 months. The price target range spans from $96 at the low end to $158 at the high end, suggesting a potential 35.65% change from the previous closing price of $97.55.

How does BioNTech SE stock forecast compare to its benchmarks?

BioNTech SE's stock forecast shows a 35.65% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BioNTech SE over the past three months?

  • July 2026: 5.00% Strong Buy, 70.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 5.26% Strong Buy, 68.42% Buy, 26.32% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 5.56% Strong Buy, 72.22% Buy, 16.67% Hold, 0% Sell, 5.56% Strong Sell.

What is BioNTech SE’s EPS forecast?

BioNTech SE's average annual EPS forecast for its fiscal year ending in December 2024 is $-3.16, marking a 0% decrease from the reported $0 in 2023. Estimates for the following years are $-3.35 in 2025, $-3.47 in 2026, $-3.25 in 2027, and $-2.46 in 2028.

What is BioNTech SE’s revenue forecast?

BioNTech SE's average annual revenue forecast for its fiscal year ending in December 2024 is $2.74B, reflecting a -28.21% decrease from the reported $3.82B in 2023. The forecast for 2025 is $2.67B, followed by $2.67B for 2026, $2.88B for 2027, and $3.64B for 2028.

What is BioNTech SE’s net income forecast?

BioNTech SE's net income forecast for the fiscal year ending in December 2024 stands at $-418M, representing a -144.93% decrease from the reported $930.3M in 2023. Projections indicate $-827M in 2025, $-822M in 2026, $-751M in 2027, and $-596M in 2028.